Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials
Phase of Trial: Phase III
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Gefitinib (Primary)
- Indications Breast cancer; Lung cancer
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca
- 03 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrial.gov record..
- 12 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrial.gov record.